0
Abstract: Poster Presentations |

INDEPTH DATABASE OF SEVERE SEPSIS PATIENTS SHOWS FEWER CARDIAC EVENTS IN DROTRECOGIN ALFA (ACTIVATED) PATIENTS VS PLACEBO PATIENTS FREE TO VIEW

Darell Heiselman, DO*; Stephen Lowry, MD; Jean-Francois Dhainaut, MD; Pierre-Francois Laterre, MD; Roland Schein, MD; Michael Seneff, MD; Jean-Pierre Sollet, MD; Antonio Artigas, MD; Jonathan Janes; Frank Booth, MD; Andreas Sashegyi, PhD; Michael Cobas Meyer, MD
Author and Funding Information

Akron General Medical Center, Akron, OH


Chest


Chest. 2005;128(4_MeetingAbstracts):378S. doi:10.1378/chest.128.4_MeetingAbstracts.378S
Text Size: A A A
Published online

Abstract

PURPOSE:  This study was done to better understand treatment risks and benefits of drotrecogin alfa (activated) (DrotAA).

METHODS:  A blinded, independent clinical evaluation committee evaluated all serious adverse events (SAEs) within INDEPTH, a 4459 patient integrated database of five clinical trials of patients with severe sepsis. Trials were conducted by a single sponsor (Eli Lilly and Company). We report the incidence of cardiac serious adverse events in placebo treated patients (n=1231) and in those treated with DrotAA (n=3228).

RESULTS:  SAEs were characterized as occurring either during the study drug infusion period or during the 28-day survival observation period. Sepsis-related clinical outcomes and sepsis-related deaths were not considered SAEs unless attributable to study drug. Despite higher survival in DrotAA, overall SAEs rates were similar in both groups. Observed rates for MI and arrhythmia were significantly lower during infusion period and at 28 days.

CONCLUSION:  These data show a possible association between DrotAA administration and a reduced rate of cardiac events in patients with severe sepsis.

CLINICAL IMPLICATIONS:  Further investigation may be justified. Table 1VariableDrotAA N=3228Placebo N=1231p Value*Infusion Period: All SAE: N (%)199 (6.2%)78 (6.3%)NSAll bleeding Arrhythmia w/o MI37 (1.15%)30 (2.44%)0.0015All non bleedingMyocardial Infarction11 (0.34%)10 (0.81%)0.04Death at 28 Days following any Infusion Period SAE87/199 (43.7%)47/78 (60.3%)0.013MI/Thrombotic All stroke/ other arterial thrombotic events28 Day Observation Period: All SAE: N (%)425 (13.2%)170 (13.8%)NSArrhythmia w/o MI54 (1.67%)43 (3.49%)<0.001Arrhythmia without MIMyocardial Infarction17 (0.53%)15 (1.22%)0.0140ther ? Death at 28 days YesDeath at 28 Days following any SAE137/425 (32.2%)72/170 (42.4.3%)0.02

In these rows only, the denominator for the calculation of percentage mortality is the number of patients at that time point with an SAE.

DISCLOSURE:  Darell Heiselman, Consultant fee, speaker bureau, advisory committee, etc. Advisory panel fee. Table 1

12:30 PM - 2:00 PM


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543